负责石头
Lv51
1000 积分
2024-02-20 加入
-
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
6天前
已完结
-
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
1个月前
已完结
-
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
2个月前
已完结
-
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
2个月前
已完结
-
Corrigendum to “Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]
2个月前
已完结
-
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
2个月前
已完结
-
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
2个月前
已完结
-
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
2个月前
已完结
-
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
3个月前
已完结
-
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
3个月前
已完结